drugset / Trial / NCT00490178

Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and Dyslipidemia

NCT00490178

Phase 3 Completed 29 enrolled Solvay Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The present study aims to assess the acceptability of a 4 week treatment of a new fixed-dose combination of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia

Timeline

Start
2007-03
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Fenofibrate Small molecule 80 mg
Subject Metformin Small molecule 1000 mg